Peroxisome proliferator-activated receptors (PPARs) in obesity and insulin resistance development;Los receptores activados por proliferadores de peroxisomas (PPARs) en el desarrollo de obesidad y resistencia a la insulina

Revista de Investigacion Clinica

Volumn 56, Issue 3, 2004, Pages 351-367

  Alemán, Gabriela ^a   Torres, Nimbe ^a   Tovar Palacio, Armando R ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Fatty acids; Insulin resistance; Obesity; Peroxisomes; PPARs

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CHEMICAL COMPOUND; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DNA; FATTY ACID; FIBRIC ACID DERIVATIVE; HEPATOCYTE NUCLEAR FACTOR 4; ICOSANOID; INTERCELLULAR ADHESION MOLECULE 1; ISOENZYME; LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; POLYUNSATURATED FATTY ACID; PROTEIN P300; RECEPTOR SUBTYPE; RETINOIC ACID RECEPTOR; STEROID RECEPTOR; TRANSCRIPTION FACTOR; VASCULAR CELL ADHESION MOLECULE 1;

ADIPOSE TISSUE; DNA RESPONSIVE ELEMENT; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ANALYSIS; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; GENE EXPRESSION; GENE TARGETING; HUMAN; INSULIN RESISTANCE; LIVER; NUTRITIONAL REQUIREMENT; OBESITY; PROTEIN EXPRESSION; PROTEIN FAMILY; RECEPTOR BINDING; REGULATORY MECHANISM; REVIEW; SKELETAL MUSCLE;

ANIMALS; HUMANS; INSULIN RESISTANCE; OBESITY; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; THIAZOLIDINEDIONES;

EID: 4544366102     PISSN: 00348376     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (163)

1. Manzano N, Torres N, Tovar AR. Mecanismo de acción de las protemas que se unen a los elementos regulatorios de esteroles (SREBPs) en la biosíntesis del colesterol y ácidos grasos. Rev Invest Clin 2002; 54: 145-53.
2. Pineda Torra I, Chinetti G, Duval C, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice. Curr Op Lipidol 2001; 12: 245-54.
3. Vamecq J, Latruffe N. Medical significance of peroxisome proliferator-activated receptors. Lancet 1999; 354: 141-8.
4. de Duve C, Baudhuin P. Peroxisomes (microbodies and related particles). Phisiol Rev 1966; 46: 323-57.
5. Mannaerts GP, Van Veldhoven PP. Metabolic role of mammalian peroxisomes. Basingstoke: Taylor and Francis. 1993.
6. Reddy JK, Mannaerts GP. Peroxisomal lipid metabolism. Ann Rev Nutr 1994; 14: 343-70.
7. Tolbert NE. Metabolic pathways in persoxisomes and glyoxisomes. Ann Rev Bioehem 1981; 50: 133-7.
8. Van den Bosch H, Shutgens RBH, Wanders RJ, Tager JM. Biochemistry of peroxisomes. Ann Rev Biochem 1992; 61: 157-97.
9. Reddy JK, Azarnoff DL, Hignite CE. Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens. Nature 1980; 283: 397-8.
10. Rao MS, Reddy JK. Peroxisome proliferation and hepatocarcinogenesis. Carcinogenesis 1987; 8: 631-6.
11. Rao MS, Ide H, Alvares L, Subbarao V, Reddy JK, Hechter O, Yeldandi AV. Comparative effects of dehydroepiandrosterone and related steroids on peroxisome proliferation in rat liver. Life Sci 1993; 52: 1709-16.
12. Lock EA, Mitchell AM, Elcombe CR. Biochemical mechanisms of induction of hepatic peroxisome proliferation. Ann Rev Pharmacol Toxicol 1989; 29: 145-63.
13. Heymans HSA, Schutgens RBH, Tan R, van den Bosch H, Borst P. Severe plasmalogen deficiency in tissues of infants without peroxisomes (Zellweger syndrome). Nature 1983; 6: 69-70.
14. Lazarow PB, de Dove C. A fatty acyl-CoA oxidizing systems in rat liver peroxisomes; enhancemente by clofibrate, a hypolipidemic drug. Proc Natl Acad Sci USA 1976; 73: 2043-6.
15. Reddy JK, Goel SK, Nemali MR, Carrino JJ, Laffler TG, Reddy MK, Sperbeck SJ, Osumi T, Hashimoto T, Lalwani ND, et al. Transcriptional regulation of peroxisome fatty acyl-CoA oxidase and enoyl-CoA hydratase/3-dehydroxyacyl-CoA dehydrogenase in rat liver by peroxisome proliferators. Proc Natl Acad Sci USA 1986; 83: 1747-51.
16. Chevalier S, Macdonald N, Roberts RA. PPAR alpha-mediated responses in the rodent liver: a holistic biochemical view. Curr Protein Pept Sci 2000; 1: 325-38.
17. Issemann I, Green S. Activation of a member of the steroid receptor hormone superfamily by peroxisome proliferators. Nature 1990; 347: 645-50.
18. Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 1996; 37: 905-25.
19. Roberts RA. Peroxisome proliferators: mechanisms of adverse effects in rodents and molecular basis for species differences. Arch Toxicol 1999; 73: 413-8.
20. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990; 347: 645-50.
21. Clarke SD, Thuillier P, Baillie R, Sha X. Peroxisome proliferator-activated receptors: a family of lipid-activated transcription factors. Am J Clin Nutr 1999; 70: 566-71.
22. Mangelsdorf DJ, Evans RM. The RXR heterodimers and orphan receptors. Cell 1995; 83: 841-50.
23. Mukherjee R, Davies PJA, Crombie DL. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 1997; 386: 407-10.
24. Thuillier P, Baillie R, Sha X, Clarke SD. Cytosolic and nuclear distribution of PPARγ2 in differentiating 3T3-L1 preadipocytes. J Lipid Res 1998; 39: 2329-38.
25. Miyata KS, Zhang B, Marcus SL, Capone JP, Rachubinski RA. Chicken ovalbumin upstream promoter transcription factor (COUP-TF) binds to a peroxisome proliferator-responsive element and antagonizes peroxisome proliferator-mediated signalling. J Biol Chem 1993; 268: 19169-72.
26. Winrow CJ, Marcus SL, Miyata KS, Zhang B, Capone JP, Rachubinski RA. Transactivation of the peroxisome proliferatoractivated receptor is differentially modulated by hepatocyte nuclear factor-4. Gene Expr 1994; 4: 53-62.
27. Baes M, Castelein H, Desmet L, Declercq PE. Antagonism of COUP-TF and PPARα,/RXRα on the activation of the malic enzyme gene promoter-modulation by 9-cis RA. Biochem Biophys Res Commun 1995; 215: 19169-72.
28. Keller H, Givel F, Perroud M, Wahli W. Signaling cross-talk between peroxisome proliferator-activated receptor/retinoid X receptor and estrogen receptor through estrogen response elements. Mol Endocrinol 1995; 9: 794-804.
29. Nunez SB, Medin JA, Braissant O, Kemp L, Wahli W, Ozato K, Segars JH. Retinoid X receptor and peroxisome proliferator-activated receptor activate an estrogen responsive gene independent of the estrogen receptor. Mol Cell Endocrinol 1997; 127: 27-40.
30. Chu R, Madison LD, Lin Y, Kopp P, Rao MS, Jameson JL, Reddy JK. Thyroid hormone (T3) inhibits ciprofibrate-induced transcription of gene encoding β-oxidation enzymes: crosstalk between peroxisome proliferator and T3 signaling pathways. Proc Natl Acad Sci USA 1995; 92: 11593-7.
31. Juge-Aubry CE, Gorla-Bajsczak A, Pernin A, Lemberger T, Wahli W, Burger AG, Meier CA. Peroxisome proliferator-activated receptor mediates cross-talk with thyroid hormone receptor by competition for retinoid X receptor: possible role of leucine zipper-like heptad repeat. J Biol Chem 1995; 270: 18117-22.
32. Lemon BD, Freedman LP. Nuclear receptor cofactors as chromatin remodelers. Curr Op Gen Dev 1999; 9: 499-504.
33. Palmer CNA, Hsu M-H, Griffin KJ, Johnson EF. Novel sequence determinants in peroxisome proliferator signaling. J Biol Chem 1995; 270: 16114-21.
34. Zhu Y, Qi C, Calandra C, Rao M, Reddy JK. Cloning and identification of mouse steroi receptor coactivator of peroxisome proliferator-activated receptor γ. Gene Expr 1996; 6: 185-95.
35. Picard F, Géhin M, Annicotte JS, Rocchi S, Champy MF, O'Malley Bw, Chambon P, Auwerx J. SRC-1 and TIF2 control energy balance between white and brown adipose tissues. Cell 2002; 111: 931-41.
36. Glass CK, Rose DW, Rosenfeld MG. Nuclear receptor coactivators. Curr Op Cell Biol 1997; 9: 222-32.
37. Janknecht R, Hunter T. Transcription- a growing coactivator network. Nature 1996; 383: 22-3.
38. Shikama N, Lyon J, Lathangue NB. The p300/CBP family: integrating signals with transcription factors and chromatin. Trends Cell Biol 1997; 7: 230-6.
39. Yamauchi T, Oike Y, Kamon J, Waki H, Komeda K, Tsuchida A, Date Y, Li MX, Miki H, Akanuma Y. Increased insulin sensitivity despite lipodystrophy in Crebbp heterozygous mice. Nat Genet 2002; 30: 221-6.
40. DiRenzo J, Soderstrom M, Kurokawa R, Ogliastro MH, Ricote M, Ingrey S, Horlein A, Rosenfeld MG, Glass CK. Peroxisome proliferator -activated receptors an retinoic acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators and corepressors. Mol Cell Biol 1997; 17: 2166-76.
41. Zamir I, Zhang J, Lazar MA. Stoichiometric and steric principles governing repression by nuclear hormone receptors. Genes Dev 1997; 11: 835-46.
42. Hu E, Kim JB, Sarraf P, Spiegelman BM. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARγ. Science 1996; 274: 2100-3.
43. Shalev A, Siegrist-Kaiser CA, Yen PM, Wahli W, Burger AG, Chin WW, Meier CA. The peroxisome proliferator-activated receptor a is a phosphoprotein: Regulation by insulin. Endocrinology 1996; 137: 4499-502.
44. Werman A, Hoolenberg A, Solanes G, Bjorbaek C, Vidal-Puig AJ, Flier JS. Ligand- independent activation domain in the N terminus of peroxisome proliferator-activated receptor γ (PPAR γ). J Biol Chem 1997; 272: 20230-5.
45. Juge-Aubry CE, Hammar E, Siegrist-Kaiser CA, Pernin A, Takeshita A, Chin WW, Burger AG, Meier CA. Regulation of the transcriptional activity of the peroxisome proliferator-activated receptor alpha by phosphorilation of a ligand-independent trans-activating domain. J Biol Chem 1999; 274: 10505-10.
46. Zhang B, Bergerl J, Zhou G, Elbrech A, Biswas S, White-Carrington S, Szalkowski D, Moller DE. Insulin-and mitogen-activated protein kinase-mediated phosphorilation and activation of peroxisome proliferator-activated receptor gamma. J Biol Chem 1996; 271: 31771-4.
47. Lazennec G, Canaple L, Saugy D, Wahli W. Activation of peroxisome proliferator-activated receptors (PPARs) by their ligands and protein kinase A activators. Mol Endocrinol 2000; 14: 1962-75.
48. Adams M, Reginato MJ, Shao D, Lazar MA, Chatterjee VK. Transcriptional activation by peroxisome proliferator-activated receptor g is inhibited by phosphorylation at a consensus mitogen activated protein kinase site. J Biol Chem 1997; 271: 5128-32.
49. Camp HS, Tafuri SR. Regulation of peroxisome proliferator-activated receptor gamma activity by mitogen-activated protein kinase. J Biol Chem 1997; 272: 10811-6.
50. Camp HS, Tafuri SR, Leff T. c-Jun N-terminal kinase phosphorylates peroxisome proliferator-activated receptor-gammal and negatively regulates its transcriptional activity. Endocrinology 1999; 140: 392-7.
51. Martin G, Duez H, Blanquart C, Berezowski V, Poulain P, Fruchart JC, Najib-Fruchart J, Glineur C, Staels B. Statin-induced inhibition of the Rho-signaling pathway activates PPARα and induces HDL apoA-1. J Clin Invest 2001; 107: 1423-32.
52. Holmberg CI, Tran SET, Eriksson JE, Sistonen L. Multisite phosphorylation provides sophisticated regulation of transcription factors. TiBS 2002; 27: 619-27.
53. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocrine Rev 1999; 20: 649-88.
54. van Bilsen M, van der Vusse GJ, Gilde AJ, Lindhout M, van Der Lee KA. Peroxisome proliferator-activated receptors: lipid binding proteins controling gene expression. Mol Cell Biochem 2002; 239: 131-8.
55. van der Vusse GJ, Van Bilsen M, Glatz JF, Hasselbaink DM, Luiken JJ. Critical steps in cellular fatty acid uptake and utilization. Mol Cell Biochem 2002; 239: 9-15.
56. Gottlicher M, Widmark E, Li Q, Gustafisson JA. Fatty acids activate a chimera of the clofibric activated receptor and the glucocorticoid receptor. Proc Natl Acad Sci USA 1992; 89: 4653-7.
57. Kliewer SA, Sundseth SS, Jones SA. Fatty acids and eicosanoids regulate gene expression trough direct interactions with peroxisome proliferator-activated receptors α and γ. Proc Natl Acad Sci USA 1997; 94: 4318-23.
58. Expert pAnel on detection e, and treatment of high blood cholesterol in adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001; 285: 2486-97.
59. Kraegen EW, Clark PW, Jenkins AB, Daley EA, Chisholm DJ, Storlien EH. Development of muscle insulin resistance after liver insulin resistance in high fat-fed rats. Diabetes 1991; 40: 1397-403.
60. Storlein LIL Kraegen EW, Chisholm DJ, Ford GL, Bruce DG, Pascoe WS. Fish oil prevents insulin resistance induced by high fat feeding in rats. Science 1987; 237: 885-8.
61. Jump DB, Clarke SD, MacDougald OA, Thelen A. Polyunsaturated fatty acids inhibit S14 gene transcription in rat liver and cultured hepatocytes. Proc Natl Acad Sci USA 1993; 90: 8454-8.
62. Jump DB, Clarke SD, Thelen A, Liimatta M. Coordinate regulation of glycolytic ad lipogenic gene expression by polyunsaturated fatty acids. J Lipid Res 1994; 35: 1076-84.
63. Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W. The PPARα - leukotriene B4 pathway to inflammation control. Nature 1996;384: 39-43.
64. Kliewer SA, Lehnard JM, Willson TM, Patel I, Morris DC, Lehman JM. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor g and promotes adipocyte differentiation. Cell 1995; 83: 813-9.
65. Yu K, Bayona W, Kallen CB, Harding HP, Ravera CP, McMahon G, Brown M, Lazar MA. Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J Biol Chem 1995; 270: 23975-83.
66. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994; 331: 1188-93.
67. Lehman J, Moore LB, Smith-Oliver TA, Wilkinson WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand por peroxisome proliferator-activated receptor γ (PPAR γ). J Biol Chem 1995; 270: 12953-6.
68. Auboeuf D. Rieusset J, Fajas L, Valier P, Frering V, Riou JP, Staels B, Quwerx J. Laville M, Vidal H. Tissue distribution and quantification of the expression of mRNAs of peroxisoine proliterator-activated receptors and liver X receptor-a in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 1997; 48: 1319-27.
69. Kersten S, Mandard S, Escher P, Gonzalez FJ, Taluri S, Desvergne B, Wahli W. The peroxisome proliferator-activated receptor a regulates amino acid metabolism. FASEB J 2001; 15: 1971-8.
70. Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli W. Peroxisome proliferator-activated receptor a mediates the adaptive response to fasting. J Clin Invest 1999; 103: 1489-98.
71. Leone TC, Weinheimer CJ, Kelly DP. A critical role for the peroxisome proliferator-activated receptor α (PPAR α) in the cellular Fasting response: The PPAR α-null mouse as a model of fatty acid oxidation disorders. Proc Natl Acad Sci USA 1999; 96: 7473-8.
72. Lernberger T, Saladin R, Vazquez M, Assimacopoulos F, Staels B, Desvergne B, Wahli W, Auwerx J. Expression of the peroxisome proliferator-activated receptor α gene is stimulated by stress and follows a diurnal rythm. J Biol Chem 1996; 271: 1764-9.
73. Costet P, Legendre C, More J, Edgar A, Galtier P, Pinedu T. Peroxisome proliferator-activated receptor α-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis. J Biol Chem 1998; 273: 29577-85.
74. Djouadi F, Weinheimer CJ, Saffitz JE, Pitchford C, Bastin J, Gonzalez FJ, Kelly DP. A gender-related defect in lipid metabolism and glucose homeostasis in peroxisome proliferator-activated receptor α-deficient mice. J Clin Invest 1998; 102: 1083-91.
75. Guerre-Millo M, Rouault C, Poulain P, André J, Poitout V, Peters JM, Gonzalez FJ, Fruchart JC, Reach G, Staels B. PPARa-null mice are protected from high-fat diet induced insulin resistance. Diabetes 2001; 50: 2809-14.
76. Muoio DM, MacLean PS, Lang DB, Li S, Hournard JA, Way JM, Winegar DA, Corton JC, Dohm GL, Kraus WE. Fatty acid homeostasis and induction of lipid regulatory genes in skeletal muscles of peroxisome proliferator-activated receptor (PPAR) a Knock-out mice. Evidence for compensatory regulation by PPARd. J Biol Chern 2002; 277: 26089-97.
77. Tontonoz P, Hu E, Devine J, Beale EG, Spiegelman BM. PPAR γ2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene. Mol Cell Biol 1995; 15: 351-7.
78. Tobin KA, Steineger HH. Alberti S, Spydevold O, Ausverx J, Gustafsson JA, Nebb Hl. Cross-talk between Fatty acid cholesterol metabolism mediated by liver X receptor-alpha. Mol Endocrinol 2000; 14: 741-52.
79. Bertolotti M, Concari M, Loria P, Abate N, Pinetti A, Guicciardi ME, Carulli N. Effects of different phenotypes of hyperlipoproteinemia and of treatment with fibric acid derivatives on the rates of cholesterol 7 alpha-hydroxylation in humans. Arterioscler Thromb Vasc Biol 1995; 15: 1064-9.
80. Marrapodi M, Chiang JY. Peroxisome proliferator-activated receptor alpha (PPAR alpha) and agonist inhibit cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription. J Lipid Res 2000; 41: 514-20.
81. Patel DD, Knight BE, Soutar AK, Gibbons GF, Wade DP. The effect of peroxisome-proliferator-activated receptor-α on the activity of the cholesterol 7α-hydroxilase gene. Biochem J 2000; 351: 747-53.
82. Hunt MC, Yang YZ, Eggertsen G, Cameheim CM, Gafvels M, Einarsson C, Alexson SE. The peroxisomne proliferator-activated receptor alpha (PPARalpha) regulates bile acid biosynthesis. J Biol Chem 2000; 275: 28947-53.
83. Edgar AD, Tomkiesvicz C, Costet P, Legendre C, Aggerbeck M, Bouguet J, Staels B, Guyomard C, Pineau T, Barouki R. Fenofibrate modifies transaminase gene expression via a peroxisome proliferator activated receptor α-dependent pathway. Toxicol Lett 1998; 98: 13-23.
84. Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ, Fruchart JC, Tedgui A, Haegeman G, Staels B. Peroxisome proliferator activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem 1999; 274: 32048-54.
85. Marx N, Sukhova GK, Collins P, Libby J, Plutzky J. PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 1999; 99: 3125-31.
86. Pasceri V, Wu HD, Willerson JT, Yeh ET. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator -activated receptor-gamma activators. Circulation 2000;101: 235-8.
87. Escher P, Braissant O, Basu-Moclak S, Michalik L, Wahli W, Desvergne B. Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology 2001; 142: 4195-202.
88. Wang Y-X, Lee C-H, Tien S, Yu RT, Ham J, Kang H, Evans RM. Peroxisome-prolifierator activated receptor 8 activates fat metabolism to prevent obesity. Cell 2003; 113: 159-70.
89. Oliver WR, Shenk JL, Snaith MR, Russell CS, Pluket KD, Bodkin NL, Lewis MC, Winegar DA, Sznaidman ME, Lambert MH, Xu HE, Sternbach DD, Kliewer SA, Hnsen BC, Willson TM. A selective peroxisome proliferator-activated receptor 6 agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA 2001; 98: 5306-11.
90. Schmitz G, Kaminski WE, Orso E. ABC transporters in cellular lipid trafficking. Carr Opin Lipidol 2000; 11: 493-501.
91. Gilde AJ, Van Der Lee KA, Willernsen PH, Chinetti G, Van der Leij FR, Vand der Vusse GJ, Staels B, Van Bilsen M. Peroxisome proliferator-activated receptor (PPAR) alpha and PPAR beta/delta, but not PPAR gamma, modulate the expression of genes involved in cardiac lipid metabolism. Cire Res 2003; ahead of print.
92. Zhu Y, Qi C, Korenberg JR, Chen XN, Noya D, Rao MS, Reddy JK. Structural organization of mouse peroxisome proliferator-activated receptor γ (mPPAR γ) gene: alternative promoter use and different splicing yield two mPPAR γ isoforms. Proc Natl Acad Sci USA 1995; 92: 7921-5.
93. Fajas L, Fruchart JC, Auwerx J. PPAR γ 3 mRNA: a distinct PPAR γ mRNA subtype transcribed from an independent promoter. FEBS left 1998; 438: 55-60.
94. Braissant O, Foufelle F, Scotto C, Sauca M, Wahli W. Differential expression of peroxisome proliferator-activated receptors: tissue distribution of PPAR -α, -β, and -γ in the adult rat. Endocrinology, 1996; 137: 354-66.
95. Vidal-Puig AJ, Considine RV, Jimenez-Linan M, Werman A, Pories WJ, Caro JF, Flier JS. Peroxisome prolifierator activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest 1997; 99: 2416-22.
96. Xing H, Northrop JP, Grove JR, Kilpatrick KE, Su JL, Ringold GM. TNFα-mediated inhibition and reversal adipocyte differentiation is accompanied by suppressed expression of PPAR γ without effects on Pref-1 expression. Endocrinology 1997; 138: 2776-83.
97. Amri EZ,. Bonino f. Ailhaud G, Abumrad NA, Grimaldi PA. Cloning of a protein that mediates transcriptional effects of fatty acids in preadipocytes. Homology to peroxisome proliferator-related receptors. J Biol Chem 1995; 270: 2367-71.
98. Vidal-Puig A. Jimenez-Linan M, Lowell BB, Hamann A, Hu E, Spiegelman B. Flier JS. Moller DE. Regulation of PPAR γ gene expression by nutrition and obesity in rodents. J Clin Invest 1996: 97; 2553-61.
99. Barak Y. Nelson MC. Ong ES, Jones YZ, Ruiz-Lozano P, Chien KR. Koder A. Evans RM. PPAR γ is required for placental. cardiac and adipose tissue development. Molecular Cell 1999; 4: 585-95.
100. Kersten S. Desvergne B, Wahli W. Roles of PPARs in health in disease. Nature 2000: 405: 421-4.
101. Rosen ED, Sarraf P. Troy AE, Bradwin G, Moore K, Milstone DS, Spiegelman BM, Mortensen RM. PPAR γ is required for the differentiation of adipose tissue in vivo and in vitro. Molecular Cell 1999; 4: 611-7.
102. Redonnet A, Groubet R, Noel-Suberville C, Bonilla S, Martinez A, Higueret P. Exposure to an obesity-inducing diet early affects the pattern of expression of peroxisome proliferator, retinoic acid, ad triiodothyronine nuclear receptors in the rat. Metabolism 2001; 50: 1161-7.
103. Kersten S. Peroxisome proliferator activated receptors and obesity. Eur J Pharmacol 2002; 440: 223-34.
104. Kubota N, Terauchi Y, Miki H, Tamemoto H, Yamauchi T, Komeda K, Satoh S, Ryosuke N, Ishii C, Sugiyama T, Eto K, Tsubamoto Y, Okuno A, Murakami K, Sekihara H, Hasegawa G, Naito M. Toyoshima Y, Tanaka S, Shiota K, Kitamura T, Fujita R. Ezaki O, Aizawa S, Nagai R, Tobe K, Kimura S, Kadowaki T. PPAR γ mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Molecular Cell 1999; 4: 597-609.
105. Miles PD. Barak Y, He W, Evans RM, Olefsky JM. Improved insulin-sensitivity in mice heterozygous for PPAR γ deficiency. J Clin Invest 2000; 105: 287-92.
106. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykhanen L, Kuusisto J, Laakso M, Fujimoto W, Auwerx J. A Pro 12 Ala substitution in PPAR γ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998; 20: 284-7.
107. 12 - Ala substitution in PPAR- γ is associated with resistance to development of diabetes in the general population. Diabetes 2001; 50: 891-4.
108. Ristow M, Muller-Wieland D, Pfeifer A, Krone W, Kahn R. Obesity asociated with the mutation in a genetic regulator of adipocyte differentiation. N Engl J Med 1998; 339: 953-9.
109. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83.
110. Haffner SM, Greenberg WM, Weston H, Chen K, Williams MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106: 679-84.
111. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 1996; 271: 10697-703.
112. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995; 270: 26746-9.
113. Edvardsson U, Bergstrom M, Alexanderssin M, Bamberg K, Ljung B, Dahllof B. Rosiglitazone (BRL49653), a PPAR g selective agonist, causes peroxisome proliferator like liver effects in mice. J Lipid Res 1999; 40: 1177-84.
114. Coe NR, Bernlohr DA. Physiological properties and functions of intracellular fatty acid binding proteins. Biochim Biophys Acia 1998; 1391: 287-306.
115. Memon RA, Tecott LH, Nonogaki K, Beigneux A, Moser AH, Grunfeld C, Feingold KR. Up-regulation of peroxisome proliferator-activated receptors (PPAR-α) and PPAR-γ messenger ribonucleic acid expression in the liver in murine obesity: Troglitazone induces expression of PPAR-γ-responsive adipose tissue-specific genes in the liver of obese diabetic mice. Endocrinology 2000; 141: 4021-31.
116. Boss O, Muzzin P, Giacobino JP. The uncoupling proteins, a review. J Endocrinol 1998; 139: 1-9.
117. Chavin KD, Yang S, Lin HZ, Chatham J, Chacko VP, Hoek JB, Walajtys-Rode E, Rashid A, Chen CH, Huang CC, Wu TC, Lane MD, Diehl AM. Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion. J Biol Chem 1999; 274: 5692-700.
118. Abumrad NA, Coburn C, Ibrahimi A. Membrane proteins implicated in long-chain fatty acid uptake by mammalian cells: CD36, FATP and FABPm. Biochim Biophys Acta 1999; 1441: 4-13.
119. Febbraio M, Abumrad NA, Hajjar DP, Sharma K, Cheng W, Pearce SFA, Silverstein RL. A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism. J Biol Chem 1999; 274: 19055-62.
120. Aitman TJ, Glazier AM, Wallace CA, Cooper LD, Norsworthy PJ, Wahid FN, Al-Mahali KM, Trembling PM, Mann CJ, Shoulders CC, Graf D, St Lezin E, Kurtz TW, Kren V, Prevanec M, Ibrahimi A, Abumrad NA, Stanton LW, Scott J. Identification of CD36 (FAT) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats. Nat Genet 1999; 21: 76-83.
121. Ibrahimi A, Bonen A, Blinn WD, Hajri T, Li X, Zhong K, Cameron R, Abumrad NA. Muscle specific overexpression of FAT/CD36 enhances fatty acid oxidation by contracting muscle, reduces plasma triglycerides and fatty acids, and increases plasma glucose and insulin. J Biol Chem 1999; 274: 26761-6.
122. Kruszynska YT, Mukherjee R, Jow L, Dana S, Paterniti Jr JR, Olefsky JM. Skeletal muscle peroxisome proliferator-activated receptor g expression in obesity and non-insulin-dependent diabetes mellitus. J Clin Invest 1998; 101: 543-8.
123. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, Heyman R, Briggs M, Deeb S, Staels B, Auwerx J. PPARα and PPARγ activators direct a tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J 1996; 15: 5336-48.
124. Schoonjans K, Watanabe M, Suzuki H, Mahfoudi A, Krey G, Wahli W, Grimaldi P, Staels B, Yamamoto T, Auwerx J. Induction of acyl-coenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter. J Biol Chem 1995; 270: 19269-76.
125. Cohen B, Novick D, Rubinstein M. Modulation on insulin activities by leptin. Science 1996; 274: 1185-8.
126. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Pattel HR, Ahima RS, Lazar MA. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-12.
127. Rosen ED, Spiegelman BM. PPARγ: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 2001; 276: 37731-4.
128. Kwon G, Xu G, Marshall CA, McDaniel ML. Tumor necrosis factor alpha-induced pancreatic beta-cell insulin resistance is mediated by nitric oxide and prevented by 15-deoxy-Delta 12,14-prostaglandin J2 and aminoguanidine. A role for peroxisome proliferator-activated receptor gamma activation and inos expression. J Biol Chem 1999; 274: 18702-8.
129. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y. Plasma concentrations of the novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Artheroscler Thromb Vasc Biol 2000; 20: 1595-9.
130. Smith U, Gogg S, Johansson A, Olausson T, Rotter V, Svalstedt B. Thiazolidinediones (PPARgamma agonists) but not PPAR alpha agonists increase IRS-2 gene expression in 3T3-L1 and human adipocytes. FASEB J 2001; 15: 215-20.
131. Rieusset J, Auwerx J, Vidal H. Regulation of gene expression by activation of the peroxisome proliferator-activated receptor γ with Rosiglitazone (BRL 49653) in human adipocytes. Biochem Biophys Res Comm 1999; 265: 265-71.
132. Wu Z, Xie Y, Morrison RF, Bucher NLR, Farmer SR. PPAR γ induces the insulin-dependent glucose transporter GLUT4 in absence of C/EBPa during the conversion of 3T3 fibroblast into adipocytes. J Clin Invest 1998; 101: 22-32.
133. Way JM, Harrington WW, Brown KK, Gottshalk WK, Sundsetb SS, Mansfield TA, Ramachandran RK, Wilson TM, Kliewer SA. Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues. Endocrinology 2001; 142: 1269-77.
134. Kim HI, Kim JW, Kim SH, Cha JY, Kim KS, Ahn YH. Identification and functional characterization of the peroxisomal proliferator response element in rat GLUT2 promoter. Diabetes 2000; 49: 1517-24.
135. Picard F, Auwerx J, PPAR g and glucose homeostasis. Ann Rev Nutr 2002; 22: 167-97.
136. Gampe RTJ, Montana VG, Lambert MH, Miller AB, Bledsoe RK, Milburn MV, Kliewer SA, Willson TM, Xu HE. Asymmetry in the PPAR gamma/RXR alpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors. Mol Cell 2000; 5: 545-55.
137. Rocchi S, Picard F, Vamecq J, Getman L, Potier N, Zeyer D, Dubuquoy L, Bac P, Champy MF, Plunket KD, Leesnitzer LM, Blanchard SG, Desreumaux P, Moras D, Renaud JP, Auwerx J. A unique PPAR-gamma ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol Cell 2001; 8: 737-47.
138. Chung SW, Kang BY, Kim SH, Pak YK, Cho D, Trinchieri G, Kim TS. Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interactions bttween peroxisome proliferator activated receptor gamma and nuclear factor-k B. J Biol Chem 2000; 275: 32681-7.
139. Delerive P. Peroxisome pro liferator-activated receptor activators inhibit th rombin- induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res 1999; 85: 394-402.
140. Thieringer R, Fenyk-Melody JE, Le Grand CB, Shelton BA, Detmers PA, Somers EP, Carbin L, Moller DE, Wright SD, Berger J. Activation of peroxisome proliferator-activated receptor gamma does not inhibit IL-6 or TNF-alpha responses of macrophages to lipopolisaccharie in vitro or in vivo. J Immunol 2000; 164: 1046-54.
141. Kim JB, Wright HM, Wright M, Spiegelman BM. ADD1/SRE-BP1 activates PPAR g through the production of endogenous ligand. Proc Natl Acad Sci USA 1998; 95: 4333-7.
142. Himms-Hagen J. Role of thermogenesis in the replation of energy balance in relation to obesity. Can J Physiol Pharmacol 1989; 67: 394-401.
143. Lee Y, Hirose H, Zhou Y-T, Esser V, McGarry JD, Unger RH. Increased lipogenic capacity of the islets of obese rats. A role in the pathogenesis of NIDDM. Diabetes 1997; 46: 408-13.
144. Shimabukuro M, Zhou Y-T, Levi M, Unger RH. Lipoapoptosis in beta-cells of obese prediabetic fa/fa rats. Role of serine palmitoyl transferase overexpression. J Biol Chem 1998; 273: 32487-90.
145. Lee Y, Wang MY, Kakuma T, Wang ZW, Babcock E, McCorkle K, Higa M, Zhou Y-T, Unger RH. Liporegulation in diet-induced obesity. The antiesteatotic role of hyperleptinemia. J Biol Chem 2001; 276: 5629-35.
146. Unger RH. Lipotoxic diseases. Ann Rev Med 2002; 53: 319-36.
147. Dietary references values for food energy and nutrients for the United Kingdom. Report of the panel on dietary reference values of the committee on medical aspects of food policy. Her Majesty's Stationery Office. London, 1991.
148. Task force on unsaturated fatty acids. Chapman and Hall. 1992.
149. FAO/WHO. Fats and oils in human nutrition report of a joint expert consultation. Food and Agriculture Organization of the United Nations and the World Health Organization. FAO Food Nutr Pap 1994; 57: 1-147.
150. Kris-Etherton PM, Shaffer Taylor D, Yu-Poth S, Huth P, Moriarty K, Fishell V, Hargrove RL, Zhao G, Etherton TD. Polyunsaturated fatty acids in the food chain in the United States. Am J Clin Nutr 2000; 71: 179S-88S.
151. Holman RT. Biological activities and requirements for polyunsaturated fatty acids. Pergamon Press. New York, 1970.
152. Eritsland J. Safety considerations of polyunsaturated fatty acids. Am J Clin Nutr 2000; 71(Suppl.): 197S-201S.
153. Goodnight SH, Harris WS, Connor WE, Illingworth DR. Polyunsaturated fatty acids, hyperlipidemia, and thrombosis. Arteriosclerosis 1982; 2: 87-113.
154. Olson RE. Nutrition and genetics: an expanding frontier. Am J Clin Nutr 2003; 78: 201-8.
155. Benani A, Kremarik-Bouillaud P, Bianchi A, Netter P, Minn A, Dauca M. Evidence for the presence of both peroxisome proliferator-activated receptors alpha and beta in the rat spinal cord. J Chem Neuroanat 2003; 25: 29-38.
156. Aoyama T, Peters JM, Iritani N, Nakajima T, Furihata K, Hashimoto T, Gonzalez FJ. Altered constitutive expression of fatty acid metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor a deficient mice. J Biol Chem 1998; 273: 5678-84.
157. Peters JM, Hennuyer N, Staels B, Fruchart JC, Fievet C, Gonzalez FJ, Auwerx J. Alterations in lipoprotein metabolism in peroxisome pro liferator-activated receptor a deficient mice. J Biol Chem 1997; 272: 27307-12.
158. Pan DA, Mater MK, Thelen AP, Peters JM, Gonzalez FJ, Jump DB. Evidence against the peroxisome proliferator-activated receptor a (PPARa) as the mediator for polyunsaturated fatty acid suppression of hepatic L-pyruvate kinase gene transcription. J Lipid Res 2000; 41: 742-51.
159. Lemberger T, Staels B, Saladin R, Desvergne B, Auwerx J, Wahli W. Regulation of the peroxisome proliferator-activated receptor a gene by glucocorticoids. J Biol Chem 1994; 269: 24527-30.
160. Steineger HH, Sorensen HN, Tugwood JD, Skrede S, Spydevold O, Gautvik KM, Dexamethasone and insulin demonstrate marked and opposite regulation of the steady-state mRNA level of the peroxisomal proliferator-activated receptor (PPAR) in hepatic cells - hormonal modulation of fatty acid induced transcription. Eur J Biochem 1994; 225: 967-74.
161. Peters JM, Lee SS, Li W. Growth, adipose, brain and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator activated receptor beta (delta). Mol Cell Biol 2000; 20: 5119-28.
162. Spiegelman BM. PPAR g adipogenic regulator and thiazolidinedione receptor. Diabetes 1998; 47: 507-14.
163. Kliewer SA, Willson TM. The nuclear receptor PPAR g: bigger than fat. Curr Op Genet Dev 1998; 8: 576-81.